FIELD: medicine, pharmacy.
SUBSTANCE: invention refers to biochemistry. An isolated antibody or antigen-binding fragment that is bound to human CD40 and acts as agonists of CD40 is described. An isolated polynucleotide encoding an isolated antibody or antigen-binding fragment thereof, an expression vector containing an isolated polynucleotide isolated host cell to produce an antibody or antigen-binding fragment thereof are described. A composition for treatment or alleviation of a disease or disorder associated with CD40, comprising a physiologically acceptable carrier and a therapeutically effective amount of the isolated antibody or antigen-binding fragment thereof is presented. Methods for treatment or alleviation of symptoms for patients having cancer, reduction of symptoms for patients having autoimmune diseases, alleviation of symptoms for patients having inflammatory diseases, including composition injection are presented.
EFFECT: invention increases the variety of CD40 antagonists.
29 cl, 18 dwg, 1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USING ANTI-CD40-ANTIBODIES | 2008 |
|
RU2491095C2 |
| HUMANISED ANTI-CD40-ANTIBODIES AND METHODS OF APPLICATION THEREOF | 2006 |
|
RU2407544C2 |
| ANTIBODIES AGAINST CD40 AND THEIR USE | 2018 |
|
RU2796413C2 |
| ANTI-CD40-ANTIBODIES, APPLICATION AND METHODS | 2012 |
|
RU2649055C2 |
| ANTIBODIES TO CD40 AND METHODS OF USE THEREOF | 2016 |
|
RU2715597C2 |
| ANTI-IDIOTYPIC ANTIBODIES AND METHODS RELATED TO THEM | 2017 |
|
RU2773355C2 |
| APPLICATION OF ANTI-CD40-ANTIBODIES | 2006 |
|
RU2442606C2 |
| gp41-NEUTRALIZING ANTIBODIES AND THEIR APPLICATION | 2012 |
|
RU2624046C2 |
| HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED DEATH 1 (PD-1) PROTEIN AND CANCER TREATMENT METHOD USING ANTI-PD-1-ANTIBODIES SEPARATELY OR COMBINED WITH OTHER IMMUNOTHERAPEUTIC AGENTS | 2013 |
|
RU2599417C2 |
| ANTIBODIES TO PROGRAMMED CELL DEATH PROTEIN 1 | 2018 |
|
RU2812915C2 |
